Their research focused on a lysine-arginine rich peptide, WT1-pTj, derived from WT1’s zinc finger domain, evaluating its potential to work as a vaccination strategy in harnessing an antitumor-specific immune response against melanoma. This evidence concerns the gene WT1 and melanoma.